January 13, 2026

FDA Drops Warning From GLP-1 RAs

The FDA asked manufacturers to remove suicidal ideation and behavior warnings from select GLP-1 RAs after a comprehensive safety evaluation.

Conexiant

January 13, 2026

FDA Drops Warning From GLP-1 RAs

The FDA asked manufacturers to remove suicidal ideation and behavior warnings from select GLP-1 RAs after a comprehensive safety evaluation.

Conexiant

January 07, 2026

Protein-First Policy Hits US Tables 

New 2025 to 2030 Dietary Guidelines for Americans shift focus to whole foods, full-fat dairy, and protein prioritization while targeting ultraprocessed products as chronic disease drivers

Conexiant

January 02, 2026

NK-1 Drug Fills Motion Sickness Gap

Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.

Conexiant

December 23, 2025

FDA OKs First Oral GLP-1 for Obesity

An oral GLP-1 option entered obesity care with outcomes similar to injectable therapy.

Conexiant

December 16, 2025

FDA OKs Addyi for Postmenopausal Women

Flibanserin approved to treat hypoactive sexual desire disorder in postmenopausal patients under 65

Conexiant

December 15, 2025

Doctors Push Back on FDA Antidepressant Fears

After an FDA roundtable raised alarms about antidepressant use in pregnancy, physicians warn the rhetoric could fuel fear, stigma, and dangerous gaps in care.

KFF Health News

December 03, 2025

Ranitidine’s return 'unlikely to provide greater clinical benefit'

New formulation incorporates stronger manufacturing controls and stability measures to prevent NDMA from forming.

Conexiant

November 21, 2025

Which Antidepressants Shift Physiology?

Researchers found differences in how antidepressants affect weight, blood pressure, heart rate, and other physiological parameters.

Conexiant